Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
07:30am, Tuesday, 29'th Jul 2025
– ARCALYST ® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $625 - $640 million �
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
04:01pm, Thursday, 24'th Jul 2025
LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
07:00pm, Wednesday, 02'nd Jul 2025
Explore the exciting world of Kiniksa Pharmaceuticals (KNSA 0.99%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market tren
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
10:30am, Wednesday, 02'nd Jul 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind
01:37pm, Tuesday, 01'st Jul 2025
Biotech stock Kiniksa soared after first-quarter results on April 29. Shares are near a buy point of 28.15.
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast
08:15am, Monday, 16'th Jun 2025
Kiniksa Pharmaceuticals has delivered strong share price performance this year thanks to a strong start to the year for Arcalyst. Medicare redesign with improved patient affordability has boosted Arca
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
07:00am, Thursday, 05'th Jun 2025
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for monthly dosing – – Presentatio
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
04:01pm, Thursday, 29'th May 2025
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June:
Kiniksa Pharmaceuticals: Making Steady Progress
04:51pm, Monday, 05'th May 2025
Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimis
– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory dise
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
03:07pm, Tuesday, 29'th Apr 2025
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
09:36am, Tuesday, 29'th Apr 2025
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share.
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
07:30am, Tuesday, 29'th Apr 2025
– ARCALYST ® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million �
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
04:01pm, Thursday, 24'th Apr 2025
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
10:40am, Tuesday, 08'th Apr 2025
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year.
